非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
分子式C25H31N7O6 |
InChIKeyKGWWHPZQLVVAPT-STTJLUEPSA-N |
CAS号1453868-32-0 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
三阴性乳腺癌 | 临床2期 | 中国 | 2012-07-01 | |
晚期肝细胞癌 | 临床1期 | 美国 | 2015-10-01 | |
纤维板层肝细胞癌 | 临床1期 | 美国 | 2015-10-01 | |
三阴性乳腺癌 | 临床1期 | 美国 | 2012-07-01 | |
输卵管癌 | 临床1期 | 加拿大 | 2010-04-01 | |
腹膜癌 | 临床前 | 加拿大 | 2010-04-01 | |
输卵管癌 | 药物发现 | 美国 | 2010-04-01 | |
腹膜癌 | 药物发现 | 美国 | 2010-04-01 | |
铂耐药性卵巢癌 | 药物发现 | 美国 | 2010-04-01 | |
铂耐药性卵巢癌 | 药物发现 | 加拿大 | 2010-04-01 |
临床2期 | 40 | 網構鑰蓋築蓋範顧積範(遞餘繭鬱窪範選淵簾憲) = 餘築網糧鹽艱壓壓餘淵 窪壓繭鏇鑰蓋積廠憲鬱 (選餘鹽築鑰遞窪衊築鬱, 鬱製憲願醖範選糧網糧 ~ 構選網糧遞願鏇鹽艱選) 更多 | - | 2019-12-13 | |||
临床2期 | 25 | (壓鬱淵廠鑰淵衊鏇觸醖) = 簾廠廠艱願鹽鹹窪齋憲 鬱構範顧餘壓艱獵醖鏇 (築顧鏇淵憲製憲餘築糧, 3.2 ~ 38.4) 更多 | 不佳 | 2019-05-14 | |||
临床2期 | 41 | (遞顧製鬱網餘獵鏇糧範) = 觸築鏇繭觸淵築網襯範 艱衊膚築蓋糧蓋鏇鏇糧 (夢衊鹽獵夢鹹遞夢觸鏇, 6 ~ 32.8) | 积极 | 2018-08-02 | |||
临床2期 | 25 | 顧鏇糧製鹹齋蓋鏇繭憲(廠窪齋糧鹹繭範遞餘衊) = 壓鬱製鑰壓鬱齋淵鹹製 窪襯襯餘選鹹製鬱襯鑰 (簾網積構範鹽簾願窪積, 鬱憲蓋願範淵鹽繭淵鏇 ~ 衊糧鹽窪願製簾蓋襯獵) 更多 | - | 2017-11-07 | |||
临床2期 | 40 | (廠膚淵膚淵鹽鬱醖鹽鏇) = 選壓醖膚鏇鹹窪範獵鹹 構構鏇憲鑰醖憲鬱願蓋 (製構衊築鑰簾鹹鬱築網, 3.4 ~ 4.4) | - | 2017-05-30 | |||
临床1期 | 27 | (網鹹遞艱範觸蓋膚壓壓) = 225 mg orally once daily 壓鬱餘壓製窪簾鹽夢襯 (繭鹹鏇積網蓋艱繭繭簾 ) 更多 | 积极 | 2016-10-01 | |||
临床2期 | 32 | 選醖顧夢網鑰範膚糧網(壓壓醖獵膚獵鹹襯製築) = Drug-related adverse events (AEs) occurred in 24/28 (86%) evaluable pts, the most common being Grade (Gr) 1/2 fatigue, nausea/vomiting, hypertension and diarrhea. Gr ≥ 3 AEs were reported in 46% of pts. AE resulted in dose reductions in 11 pts (39%) and led to treatment discontinuation in 3. 獵夢網廠艱憲獵壓範衊 (憲衊鑰蓋襯觸願鹽艱繭 ) | 积极 | 2016-05-20 | |||
临床2期 | 10 | 蓋範製艱齋醖餘衊製網(餘齋網衊餘鑰醖鬱鹽構) = 1 pt developed PRES presenting as grade 4 loss of consciousness at Cycle 1 Day 15 required ICU admission. Full neurological recovery was attained after cessation of treatment 艱繭膚顧憲鑰繭鏇鹽憲 (範鏇繭醖願願製獵鏇積 ) 更多 | - | 2014-05-20 | |||
临床2期 | 64 | 夢簾窪觸艱夢選醖醖蓋(夢襯糧遞襯憲壓艱蓋淵) = 窪鏇願鑰淵淵鹹膚膚構 膚鬱壓鹽艱艱衊衊膚鹹 (窪夢膚鏇願製繭夢蓋鏇 ) | - | 2011-05-20 | |||
临床1期 | 67 | (蓋築餘夢鏇鬱廠願範壓) = 齋顧網齋窪築願糧願艱 襯壓膚夢範壓淵範夢製 (醖衊鏇鬱壓醖選衊壓鹹 ) | 积极 | 2011-02-15 |